SCHEMBL4415214

SCHEMBL4415214

COc1cc(-n2c(=O)[nH]c3cc(NCc4ccc(F)cc4)ccc3c2=O)ccc1C(=O)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.49
TP53 P04637 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
USP2 O75604 1/20 0.38
MAPT P10636 3/20 0.37
CCR4 P51679 3/20 0.37
EGLN3 Q9H6Z9 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
HTR3A P46098 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4425407 0.91 P2RY12 (0.51) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL4413815 0.91 P2RY12 (0.51) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL4415290 0.91 P2RY12 (0.52) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL4418832 0.87 P2RY12 (0.54) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL4421833 0.86 USP2 (0.49) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL4426718 0.85 P2RY12 (0.49) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL13635114 0.84 P2RY12 (0.66) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL4412718 0.84 P2RY12 (0.54) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL13635098 0.84 MEN1 (0.53) P2RY12TP53SMN1; SMN2MEN1KMT2A
SCHEMBL6094405 0.83 P2RY12 (0.59) P2RY12TP53SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
US-7109332-B2 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PFKP, DPP3, P2RY13 P2RY12 21/4885TP53 3744/4885SMN1; SMN2 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.